(LifeSiteNews) – Abortion pill distributor Carafem appears to be working with influencers to turn apparent chemical abortions into social media content, a Live Action investigation has found.
Founded in Maryland in 2013, Carafem bills itself as a “national nonprofit providing compassionate, people-centered abortion and sexual healthcare,” providing abortions by mail as well as in-person at locations in Atlanta, Chicago, and the nation’s capital. In addition to facilitating chemical abortions, it offers customers the option of stockpiling abortion pills for future use.
Live Action’s Sami Parker reports that she identified several examples of social media videos about “at-home abortions,” all specifically identifying Carafem as the provider of their pills and bearing #carafempartner hashtags.
“Let’s get ready for my at-home abortion with Carafem,” one said. “You’re probably wondering, ‘What should I wear for an at-home abortion?’ Well, you can wear whatever you want, but I prefer pajamas. Choosing an at-home abortion with Carafem allows you to be as comfortable as you want in whatever you want. So if you’re seeking abortion … reach out to Carafem today.”
“I had an abortion. The package from Carafem includes helpful things like mints, tea, a hot pack, a pad, and nausea medication,” another said. “And I just wanna grab a couple more things so I can make sure I am prepared and comfortable during my medication abortion. Now that I’m home and unpacking my self-care items from Target and I’m looking over the items from Carafem, I know that I am ready for my medication abortion in the comfort of my own apartment.”
The “partner” branding appears to indicate that the videos are part of some kind of paid promotional arrangement, which also means the creators would not be at liberty share any negative experiences with the product they are promoting – making these videos advertisements masquerading as women sharing authentic experiences (which also means whether or not they actually had abortions is unconfirmed).
“Abortion influencer doctors talk all the time about how you can order abortion pills online, and it’s so easy, and it’s so safe, but something I’ve genuinely never heard them talk about is how risky it is,” Parker responded. “Abortion pill manufacturers claim that only .5% of women who take the abortion pill experience a serious adverse reaction. They rely on the results of 10 clinical trials with a total of 30,966 participants from over a decade ago. This was before mail-order abortion pills were available. This was also before abortion pill safeguards were largely relaxed as they are today. It is outdated information at best.”
Mail-order pills have become the abortion lobby’s most potent tool for circumventing these laws and preserving abortion without Roe v. Wade. The latest data from the pro-abortion Guttmacher Institute found 1,125,930 clinical abortions in 2025, a slight increase from 2024, which Guttmacher attributed in large part to abortion pills. Planned Parenthood’s 2024–2025 annual report claims that it alone committed 434,450 abortions, a record number for the organization and eight percent more than the previous year.
The abortion lobby aggressively defends this aspect of its business despite evidence that mail-order home abortions are even more dangerous to women than abortion pills “properly” administered in a facility.
An April 2025 analysis by the Ethics and Public Policy Center (EPPC) concluded that almost 11 percent of women suffer sepsis, infection, hemorrhaging, or other major conditions after taking mifepristone, according to insurance data, joining similar findings by the Restoration of America Foundation to form a “growing body of evidence indicating that the health risks associated with mifepristone abortions are severe, widespread, and significantly underreported.” Those risks are only magnified, pro-lifers argue, when the pills are allowed to be taken in complete privacy, without medical supervision or close access to emergency services, for no other reason than to evade state pro-life laws.
Pro-lifers are currently waiting to see whether a long-awaited safety data review by the U.S. Food and Drug Administration will lead to the Trump administration restoring the in-person dispensing requirement that has enabled the abortion-by-mail scheme.
Multiple states are suing to force a restoration of the requirement; one suit has been delayed until after the November midterm elections, while oral arguments in another are slated to begin tomorrow.